tirzepatide resting heart rate increase Increase: Evidence and Monitoring Guidance Cardiovascular effects of tirzepatide -

Perhaps most telling is the comparison with GLP-1 receptor agonists as a class

Proper patient education should emphasize that injection site selection does not impact the likelihood or severity of these systemic effects

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

In a study of 2,539 adults conducted over 72 weeks, those taking between 5mg and 15mg of tirzepatide (Mounjaro) once a week experienced hair loss at a rate of between 4.9% and 5.7%, depending on the dose

Basic Results Data Element Definitions